October 2019 Br J Cardiol 2019;26:149–52 doi:10.5837/bjc.2019.033
Tariq Enezate, Jad Omran, Obai Abdullah, Ehtisham Mahmud
Introduction Systolic heart failure (SHF) in patients with severe aortic stenosis (AS) carries a worse prognosis, and aortic valve replacement improves ventricular systolic function and survival.1,2 Therefore, SHF is an indication for aortic valve replacement in severe AS.2 Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are associated with comparable survival and ventricular systolic function recovery in this group of patients.3 TAVR, however, is the recommended approach for patients with intermediate to prohibitive surgical risk; and SHF patients are often considered a high-risk group. As a re
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits